Abstract
The exploitation of genetic engineering technology has made available many protein hormones and mediators for clinical application in man; however, it is becoming progressively apparent that some of these recombinant molecules (e.g. TNF, IL-1, IL-2) retain high levels of toxicity in vivo. As a result of such observations, there is increasing interest in ways of improving the biological half-life and specificity of potential therapeutic agents. At the same time, it is also becoming apparent that many hormones/ mediators recognise several receptor subtypes distinguished by properties such as structure, affinity, specificity and tissue origin. It is probable that the different cellular receptors for hormones have evolved in order to provide an additional step in the complex regulatory process leading to a physiological response. Recent evidence also suggests some cellular receptors are released into the circulation in order to act as “carrier” proteins for hormones. Whether this effect is important to protect the relevant hormone from degradation or to provide a more optimal delivery and function is as yet unclear.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abel-Meguid, S.S., Shieh, H-S., Smith, W.W., Dayringer, H.E., Violand, B.N. and Bentle, L.A., 1987, Three dimensional structure of a genetically engineered variant of porcine growth hormone, Pr oc. Nat I.Acad. Sci., USA, 84:6434.
Aston, R., Holder, A.T., Preece, M.A. and Ivanyl, J., 1986, Potentiation of the somatogenic and lactogenic activity of human growth hormone with monoclonal antibodies, J.Endocrinol., 110:381.
Aston, R., Holder, A.T., Ivanyi, J. and Bomford, R., 1987, Enhancement of bovine growth hormone activity in vivo by monoclonal antibodies, Molec.Immunol., 24:143.
Aston, R., Cowden, W.B. and Ada, G.L., 1989, Antibody-mediated enhancement of hormone activity, Molec.Immunol., 26:435.
Aston, R., Rath jen, D.A., Holder, A.T., Bender, V., Trigg, T.E., Cowan, K., Edwards, J.A. and Cowden, W.B., 1990, Antigenic structure of bovine growth hormone: location of a growth enhancing region, (submitted for publication).
Beutler, B., Milsark, I.W. and Cerami, A.C., 1985, Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 229:869.
Bomford, R. and Aston, R., 1990, Enhancement of bovine growth hormone activity by anti-peptide auto-antibody, J.Endocrinol., in press.
Cadman, H.F. and Wallis, M., 1981, An investigation of the sites that bind human somatotropin (growth hormone) in the liver of the pregnant rabbit, Biochem.J., 198:605.
Clark, R.G., Jansson, J-O., Isakson, O. and Robinson, I.C.A.F., 1985, Intravenous growth hormone: growth responses to patterned infusion in the hophysectionized rat, J.Endocrinol., 104:53.
Frackelton, A.R. and Rotman, B., 1980, Functional diversity of antibodies elicited by bacterial beta-D-galactosidase, J.Biol.Chem., 225:5286.
Holder, A.T., Wallis, M., Biggs, P. and Preece, M.A., 1980, Effects of growth hormone, prolactin and thyroxine on body weight, somatomedin- like activity and in vivo sulphation of cartilage in hypopituitary dwarf mice, J.Endocrinol., 85:35.
Holder, A.T., Aston, R., Preece, M.A. and Ivanyi, J., 1985, Monoclonal anti- body-mediated enhancement of growth hormone activity in vivo, J.Endocrinol., 107:59.
Holder, A.T., Aston, R., Rest, J.R., Hill, D.J., Patel, N. and Ivanyi, J., 1987, Monoclonal antibodies can enhance the biological activity of thyrotrophin. Endocrinology., 120:567.
Jones, W.R., Bradley, J., Judd, S.J., Denholm, E.H., Ing, R.M.Y., Mueller, U.W., Powell, J., Griffin, P.D. and Stevens, V.C., 1988, Phase I clinical trial of a World Health Organisation birth control vaccine, Lancet, i:1295.
Miller, W.L., and Eberhardt, N.L., 1983, Structure and evolution of the growth hormone gene family. Endocrine Rev., 4:97.
Schreiber, R.D., Hicks, L.J., Celada, A., Buchmeier, N.A. and Gray, P.W., 1985, Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity, J.Immunol., 134:1609.
Shechter, Y., Chang, K.J., Jacobs, S. and Cuatrecasas, P., 1979, Modulation of binding and bioactivity of insulin by anti-insulin antibody: relation to possible role of receptor self aggregation in hormone action, Proc.Natl.Acad.Sci.USA, 76:2720.
Smith, W.C., Linzer, D.I. and Talamantes, F., 1988, Detection of two growth hormone receptor mRNAs and primary translation products in the mouse, Proc.Natl.Acad. Sci.USA, 85:9576.
Wallis, M., Daniels, M., Ray, K.P., Cottingham, J.D. and Aston, R., 1987, Monoclonal antibodies to bovine growth hormone potentiate effects of the hormone on somatanoedin C levels and growth of hypophysectionized rats, Biochem.Biophys.Res.Comm., 149:187.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Plenum Press, New York
About this chapter
Cite this chapter
Bomford, R., Aston, R. (1990). Enhancement of Hormone Activity by Monoclonal Antibodies. In: Gregoriadis, G., Allison, A.C., Poste, G. (eds) Targeting of Drugs 2. NATO ASI Series, vol 199. Springer, New York, NY. https://doi.org/10.1007/978-1-4684-9001-5_5
Download citation
DOI: https://doi.org/10.1007/978-1-4684-9001-5_5
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4684-9003-9
Online ISBN: 978-1-4684-9001-5
eBook Packages: Springer Book Archive